Navigation Links
FDA Decision Encourages Lamictal Generics

As the FDA cannot approve an abbreviated new drug application (ANDA) for a listed drug that has been withdrawn due to reasons of safety or efficacy// , the agency had to determine the reasons for the withdrawal before approving any generic version.

The investigation found no evidence of safety or efficacy issues, and the FDA has announced that it can approve ANDAs provided all other legal and regulatory requirements are met. The FDA added that the ruling was in response to a citizen's petition from a patent attorney that was filed in June 1995.

However, even if rival drug makers were to file an application for the drug, the respective company could still face a patent suit from Glaxo as the patent in the US is not due to run out until 2009. Lamictal already faces generic competition in Europe, where its patents have expired.

Lamictal (lamotrigine) is an antiepileptic drug indicated as adjunctive therapy for partial seizures in adults and pediatric patients. It is also approved for conversion to monotherapy in adults with partial seizures who are receiving treatment with a single enzyme-inducing antiepileptic drug or valproate. In addition, Lamictal is indicated for the maintenance treatment of bipolar I disorder in certain patients.

Source-Bio-Bio Technology
'"/>




Page: 1

Related medicine news :

1. Decision making made easier
2. Decision making made easier
3. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
4. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
5. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
6. HRT: A Difficult Decision
7. Decisions On End-of-Life Treatment Found To Vary From Country To Country
8. Pharma Companies May Influence The Decisions Of Medical Students
9. Critical Decisions Have To Be Taken By Mothers Of Premature Babies
10. Novel Study Unravels a New Dimension to Decision Making
11. Distinct Brain Sections Are Activated While Making Risky Decisions
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
Breaking Medicine Technology: